Merck LM-299 vs ivonescimab: how do they compare?
LM-299 and ivonescimab are separate PD-1×VEGF bispecific programs: Merck licensed LM-299 from LaNova on November 14, 2024, while Akeso licensed ivonescimab to Summit in December 2022. Merck disclosed $588 million upfront and up to $2.7 billion in milestones; Summit’s cumulative upfront consideration was $515 million after the 2024 expansion, and these deal figures do not establish which drug is more effective. On November 15, 2026 (U.S. time), Summit announced that it had received an FDA complete response letter for Akeso’s ivonescimab; the U.S. application could not be approved on the current data.
| Measure | LM-299 | Ivonescimab |
|---|---|---|
| Program / developer | LM-299: LaNova / Merck | Ivonescimab: Akeso / Summit |
| Checkpoint / VEGF target | PD-1 × VEGF | PD-1 × VEGF |
| Upfront consideration | $588 million | $515 million cumulative after expansion |
| Potential milestones | Up to $2.7 billion | Up to $4.555 billion after expansion |
Ivonescimab after the FDA letter
On November 15, 2026 (U.S. time), Summit Therapeutics announced that it had received an FDA complete response letter for Akeso’s ivonescimab. In the 438-patient HARMONi trial, primary overall survival yielded p=0.057 against a prespecified threshold of 0.0448; median overall survival was 16.8 months with ivonescimab plus chemotherapy versus 14.0 months with chemotherapy. The application could not be approved on the current data. Subsequent first-line lung cancer evidence will come from HARMONi-3 and HARMONi-7.
Sources
Read the full analysis
FDA Rejects Akeso’s Bispecific: PFS Was Not Enough — November 17, 2026